and Tim and Adefovir Combinations of Penciclovir , Lamivudine , In Vitro Antihepadnaviral Activities of

[1]  S. Locarnini,et al.  Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. , 2008, Liver.

[2]  S. Locarnini,et al.  Preclinical aspects of lamivudine and famciclovir against hepatitis B virus , 1999, Journal of viral hepatitis.

[3]  C. Gibbs,et al.  Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro , 1998, Hepatology.

[4]  P. Angus,et al.  Inhibition of Duck Hepatitis B Virus Replication by 9-(2-Phosphonylmethoxyethyl)adenine, an Acyclic Phosphonate Nucleoside Analogue , 1998, Antimicrobial Agents and Chemotherapy.

[5]  R. Tedder,et al.  Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection. , 1998 .

[6]  A. Bertoletti,et al.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. , 1998, The Journal of clinical investigation.

[7]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[8]  F. Zoulim,et al.  Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. , 1998, Journal of hepatology.

[9]  D. Richman,et al.  Summary of the III International Consensus Symposium on Combined Antiviral Therapy. , 1998, Antiviral research.

[10]  J. Cherrington,et al.  The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. , 1997, The Journal of infectious diseases.

[11]  C. Hendrix,et al.  Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. , 1997, The Journal of infectious diseases.

[12]  S. Locarnini,et al.  Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro , 1997, Hepatology.

[13]  P. Angus,et al.  Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. , 1997, Journal of hepatology.

[14]  P. Angus,et al.  Demonstration of duck hepatitis B virus in bile duct epithelial cells: Implications for pathogenesis and persistent infection , 1997, Hepatology.

[15]  E. De Clercq,et al.  HPMPC (cidofovir), PMEA (adefovir) and Related Acyclic Nucleoside Phosphonate Analogues: A Review of their Pharmacology and Clinical Potential in the Treatment of Viral Infections , 1997 .

[16]  F. Zoulim,et al.  Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription , 1997 .

[17]  T. Shaw,et al.  Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir , 1996, Hepatology.

[18]  S. Locarnini,et al.  The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo , 1996, Antimicrobial agents and chemotherapy.

[19]  E. Schiff,et al.  A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.

[20]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[21]  E. De Clercq,et al.  Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture , 1994, Antimicrobial Agents and Chemotherapy.

[22]  S. Locarnini,et al.  The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. , 1994, Virology.

[23]  S. Locarnini,et al.  In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus , 1994, Antimicrobial Agents and Chemotherapy.

[24]  E. De Clercq,et al.  Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. , 1993, Antiviral research.

[25]  E. De Clercq,et al.  Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. , 1991, Antiviral research.

[26]  I. Gust,et al.  Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B Virus in vitro using conventional antiviral agents and supercoiled‐DNA active compounds , 1990, Journal of medical virology.

[27]  J. Summers,et al.  In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. , 1990, Virology.

[28]  C. Trépo,et al.  Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: A useful system for antiviral testing , 1989, Hepatology.

[29]  J. Summers,et al.  In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus , 1986, Journal of virology.

[30]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. , 1998, Hepatology.

[31]  J. Colacino,et al.  The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection. , 1998, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[32]  P. Marion,et al.  Hepadnaviruses and hepatocellular carcinoma. , 1991, Annual review of microbiology.

[33]  M. Berenbaum.  What is synergy? , 1989, Pharmacological reviews.